Needham analyst Rajvindra Gill came out today with a research report on Micron Technology, Inc. (NASDAQ:MU) following the company’s release of its fiscal third …
In a research report released this morning, Needham analyst Rajvindra Gill reiterated a Buy rating on Micron Technology, Inc. (NASDAQ:MU), while reducing the price …
Needham analyst Chad Messer came out with commentary on ISIS Pharmaceuticals, Inc. (NASDAQ:ISIS) following recent updates from two ongoing Phase II studies with ISIS-SMNRx, a drug to …
The FDA advisory committee recommended this week that the FDA approve Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)’s Orkambi therapy to treat cystic fibrosis. By a vote …
Needham’s healthcare analyst Alan Carr weighed in today with an update on Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), after the company reported first-quarter financial results and held a …
By Carly Forster Technology company NVIDIA Corporation (NASDAQ:NVDA) dropped more than 7% in trading on May 8th after it fell short of first quarter 2015 …
In a research report released Friday, Needham analyst Alan Carr maintained a Buy rating on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with a $38 price target, after the …
By Sarah Roden Gilead Sciences (NASDAQ: GILD) released first quarter 2015 earnings on April 30. High revenues pointed to the success of Gilead’s …
In a research report released Friday, Needham analyst Rajvindra Gill upgraded shares of Cypress Semiconductor Corporation (NASDAQ:CY) from Buy to Strong Buy, while the price target is …
In a research report issued today, Needham analyst Alan Carr reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD) with a $120 price target, after …
